

1. **Novack GD**, Winters WD, Nakamura J. EEG and behavioral effects of morphine in dogs. *Proc West Pharmacol Soc* 1976;19:239-42.
2. **Novack GD**, Stark LG. Effects of benzhydryl piperazines, phenobarbital and phenytoin on maximal electroshock seizures in the rat. *Proc West Pharmacol Soc* 1977;20:63-8.
3. **Novack GD**. Benzhydryl piperazines. A neuropharmacological and psychopharmacological evaluation. Ph.D. dissertation. University of California, Davis. *Disert Abs Inter* 1977;38(6).
4. **Novack GD**, Bullock JL, Eisele JH. Fentanyl: Cumulative effects and development of short-term tolerance. *Neuropharmacol* 1978;17:77-82.
5. **Novack GD**. Symposium: Effects of histamine on three organ systems. *Proc West Pharmacol Soc* 1978;21:141-3.
6. **Novack GD**, Stark LG, Peterson SL. Anticonvulsant effects of benzhydryl piperazines on pentylenetetrazole-induced seizures in mice. *Neuropharmacol* 1978;17:659-63.
7. **Novack GD**, Stark LG. Benzhydryl piperazines and phenobarbital as discriminative stimuli in rats and mice. *Res Com Psychiat Psychol Behav* 1978;3:335-51.
8. **Novack GD**, Stark LG, Peterson SL. Anticonvulsant effects of benzhydryl piperazines on maximal electroshock seizures in rats. *J Pharmacol Exp Ther* 1979;208:480-4.
9. Cherubini E, **Novack G**, Hull CD, Buchwald NA, Levine MS. Caudate neuronal responses evoked by cortical stimulation: Contribution of an indirect corticothalamic pathway. *Brain Res* 1979;173:331-6.
10. Levine MS, Cherubini E, **Novack GD**, Hull CD, Buchwald NA. Development of responses of globus pallidus and entopeduncular nucleus neurons to stimulation of the caudate nucleus and precruciate cortex. *Exp Neurol* 1979;66:479-92.
11. **Novack GD**. Studies on the efficacy and depressant potential of muscle relaxants in mice. *Drug Development Res* 1982;2:383-6.
12. **Novack GD**, Zwolshen JM. Predictive value of muscle relaxant models in rats and cats. *J Pharmacol Methods* 1983;10:175-83.
13. **Novack GD**, Owenburg KM. Flurazepam and triazolam: dose-response and time-response evaluation on cat sleep. *Electroenceph Clin Neurophys* 1984;57:277-88.
14. Bensinger R, Keates E, Gofman J, **Novack GD**, Duzman E. Levobunolol: a three month efficacy study in the treatment of glaucoma and ocular hypertension. *Arch Ophthalmol* 1985;103:375-8.
  - Also selected for publication in Spanish Edition of *Arch Ophthalmol* 1985;1:45-8.
15. Long D, Zimmerman T, Spaeth G, **Novack GD**, Duzman E. Levobunolol: minimum concentration required to control IOP in patients with primary open-angle glaucoma or ocular hypertension. *Amer J Ophthalmol* 1985;99:18-22.
16. Berson F, Cohen H, Foerster RJ, Lass J, **Novack GD**, Duzman E. Levobunolol compared with timolol: ocular hypotensive efficacy and ocular and systemic safety. *Arch Ophthalmol* 1985;103:379-82.
  - Also selected for publication in Spanish Edition of *Arch Ophthalmol* 1985;1:41-4.
17. Cinotti A, Galin M, Silverstone D, Shin D, **Novack GD**, Duzman E, Lue JC, et. al. 0.5% and 1.0% Levobunolol compared with 0.5% timolol for the long-term treatment of chronic open-angle glaucoma and ocular hypertension. *Amer J Ophthalmol* 1985;99:11-17.
18. Silverstone DE, Cowan GM, Arkfelt F, **Novack GD**, Lue JC. Levobunolol given twice

- daily controls IOP around-the-clock. *Glaucoma* 1985;7:138-40.
19. Ober M, Scharrer A, David R, Biedner B, Lue JC, **Novack GD**, Robins DS, Duzman E. The ocular hypotensive effect and safety of levobunolol (0.5% and 1.0%) compared with 0.5% timolol in subjects with open-angle glaucoma or ocular hypertension. *Br J Ophthalmol* 1985;69:593-9.
  20. Levobunolol Study Group. Levobunolol: a beta-adrenoceptor antagonist effective in the treatment of glaucoma. *Ophthalmology* 1985;92:1271-6.
  21. Geyer O, **Novack GD**, Lazar M, Duzman E. The ocular hypotensive efficacy and safety of levobunolol (0.5% and 1%) compared with timolol (0.5%) in patients with open-angle glaucoma or ocular hypertension: a one-year study. *Ann Ophthalmol* 1986;18:289-292.
  22. Yablonski ME, **Novack GD**, Burke PJ, Cook DJ, Harmon G. The effect of levobunolol on aqueous humor dynamics. *Exp Eye Res* 1987;44:49-54.
  23. **Novack GD**, Duzman E, Lue JC, Robins DS. Levobunolol: a new beta-adrenoceptor antagonist for the treatment of glaucoma. *Proc. Second Symposium of the European Glaucoma Society*, 1985;p. 138.
  24. Duzman E, Long D, Spaeth G, **Novack GD**. Levobunolol: minimum concentration required to control IOP in subjects with primary open-angle glaucoma or ocular hypertension. *Proc. Second Symposium of the European Glaucoma Society*, 1985;p. 130.
  25. Leopold IH, Duzman E, **Novack GD**. Pharmacology of Ocular Catecholamines. IN: *Biomedical Foundations of Ophthalmology*, T.D. Duane and E.A. Jaeger (eds.), Vol. 3, Chapter 34, Harper & Rowe, Philadelphia, 1985; pp. 1-39.
  26. **Novack GD**. Book review of Aird et al.: *The Epilepsies*. *Book Reviews in the Neurosciences*, Spring 1985, Number 23.
  27. **Novack GD**. Book review of Essman: *Clinical Pharmacology of Learning and Memory*, *Book Reviews in the Neurosciences*, Summer 1985, Number 24.
  28. **Novack GD**. Book review of Carlson: *A Primer of Behavioral Pharmacology*, *Book Reviews in the Neurosciences*, Summer 1985, Number 24.
  29. Sternberg DB, Korol D, **Novack GD**, McGaugh JL. Epinephrine-induced memory facilitation: Differentiation of adrenergic receptors involved as determined by adrenergic antagonist. *Eur J Pharmacol* 1986;129:189-193.
  30. Ober M, Scharrer A, **Novack GD**, Lue JC. Die lokale subjektive Vergleichlichkeit von Levobunolol und Metipranolol in einer Doppelblind-Vergleichsstudie bei Patienten mit erhöhtem intraokularem druck. (The comfort of levobunolol and metipranolol in patients with elevated intraocular pressure.) *Ophthalmologica* 1986;192:159-64.
  31. Wandel T, Charap AD, Lewis RA, Partamian L, Cobb S, Lue J, **Novack GD**, Gaster R, Smith JA, Duzman E. Glaucoma treatment with once-daily levobunolol. *Amer J Ophthalmol* 1986;101:298-304.
  32. **Novack GD**. Minireview: Levobunolol for the long-term treatment of elevated intraocular pressure. *Gen Pharmacol* 1986;17:373-7.
  33. **Novack GD**. Review: Beta-blockers since timolol. *Survey of Ophthalmol* 1987;31:301-327.
  34. Krieglstein GK, **Novack GD**, Voepel E, Schwarzbach G, Lange U, Schunck KP, Lue JC, Glavinis EP. Levobunolol and Metipranolol: Comparative ocular hypotensive

- efficacy, safety and comfort. *Br J Ophthalmol* 1987;71:250-253.
35. **Novack GD**, Eto CY, Lue JC, Branin M-J. A post-marketing evaluation of levobunolol, a topical ophthalmic drug. *J Clin Res Drug Develop* 1987;1:197-203.
  36. **Novack GD**. Book review of Trimble: *The Psychopharmacology of Epilepsy*. *Book Reviews in the Neurosciences* (1986).
  37. **Novack GD**. Book Review of Stancer: *Guidelines for the use of Psychotropic Drugs*. *Book Reviews in the Neurosciences* (1986).
  38. Woodward DF, **Novack GD**, Williams LS, Nieves AL, Potter DE. The ocular beta-blocking activity of dihydrolevobunolol. *J Ocular Pharmacol* 1987;3:11-15.
  39. **Novack GD**, Tang-Liu DD-S, Kelley EP, Liu SS, Shen DC, Duzman E. Levobunolol plasma levels following topical administration. *Ophthalmologica* 1987;194:194-200.
  40. David R, Ober M, Masi R, Elman J, **Novack GD**, Sears M, Batoosingh A. Levobunolol and pilocarpine: Combination therapy for the treatment of elevated intraocular pressure. *Can J Ophthalmol* 1987;22:208-211.
  41. **Novack GD**, David R, Lee PF, Freeman MI, Duzman E, Batoosingh AL. The effect of changing medication regimens in glaucoma patients. *Ophthalmologica* 1988;196:23-28.
  42. Lamping K, Gofman J, Duzman E, Leopold IH, **Novack GD**. Effect of changing beta-blocker treatment in six patients allergic to timolol. *J Toxicol - Cut Ocular Toxicol* 1987;6:3 179-81.
  43. **Novack GD**, Leopold IH. Aqueous humor, cerebrospinal fluid and atriopeptin. *Am. J. Ophthalmol* 1987;104:297-300.
  44. **Novack GD**, Wandel TA, Charap AD, Lewis RA, Cobb S, Partamian L, Lue JC, Duzman E. Treating glaucoma once-a-day with levobunolol. *New Trends in Ophthalmology II* 1987;(1):54-48.
  45. Long D, Allen RC, Robin A, David R, Ober M, Scharrer A, Masi R, Elman J, Lue JC, **Novack GD**. Levobunolol concomitant with dipivefrin or pilocarpine for glaucoma therapy. *New Trends in Ophthalmology II* 1987;(1):66-70.
  46. Duzman E, **Novack GD**, Leopold IH. The ocular hypotensive effect of an  $\alpha_1$ -antagonist and an  $\alpha_2$ -antagonist in patients with glaucoma. *New Trends in Ophthalmology II* 1987;(1):145-148.
  47. Leopold IH, Potter DE, Duzman E, **Novack GD**. Pharmacology of Ocular Catecholamines. IN: *Biomedical Foundations of Ophthalmology*, T.D. Duane and E.A. Jaeger (eds). Volume 3, Chapter 34, Harper & Rowe, Philadelphia, 1988, pp 1-34.
  48. **Novack GD**, Leopold IH, Duzman E. Pharmacology of ocular beta-adrenoceptor antagonists. IN: *Biomedical Foundations of Ophthalmology*, T.D. Duane and E.A. Jaeger (eds). Volume 3, Chapter 32, Harper & Rowe, Philadelphia, 1988, pp 1-15.
  49. Allen RC, Robin AL, Long D, **Novack GD**, Lue JC, Kaplan G. A combination of levobunolol and dipivefrin for the treatment of elevated intraocular pressure. *Arch Ophthalmol* 1988;106:904-907.
  50. **Novack GD**, Leopold, IH. Review: The toxicity of topical ophthalmic beta-blockers. *J Toxicol - Cut & Ocular Toxicol* 1987;6:283-297.
  51. Wandel TA, Fishman D, **Novack GD**, Kelley EP, Chen K. Ocular hypotensive efficacy of 0.25% levobunolol once-daily. *Ophthalmology* 1988;95:252-5.
  52. Geyer O, Lazar M, **Novack GD**, Shen D, Eto CY. Levobunolol compared with timolol: A four-year study. *Br J Ophthalmol* 1988;72:892-896.
  53. Boozman FW, Carriker R, Foerster R, Allen RC, **Novack GD**, Batoosingh AL. A long-

- term evaluation of 0.25% levobunolol and timolol for the therapy of elevated intraocular pressure. *Arch Ophthalmol* 1988;106:614-8.
54. Freyler H, **Novack GD**, Menapace R, Skorpik C, Mordaunt J, Batoosingh AL. Vergleich der Wirksamkeit und Ansendungssicherheit von Levobunolol und Timolol bei Okularer Hypertonie. (English version: Comparative Ocular Hypotensive Efficacy and Safety of Levobunolol and Timolol). *Klin. Mbl. Augen.* 1988;193:257-260.
  55. Long DA, Johns GE, Mullen RS, Bowe RG, Alexander D, Epstein DL, Weiss, MJ, Masi RJ, Charap AD, Eto CY, **Novack GD**. Levobunolol and Betaxolol: a double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure. *Ophthalmology* 1988;95:735-741.
  56. Silverstone DE, **Novack GD**, Kelley EP, Chen KS. Prophylactic treatment of intraocular pressure elevations after Neodymium:YAG laser posterior capsulotomies and extracapsular cataract extractions with levobunolol. *Ophthalmology* 1988;95:713-718.
  57. Hayashi M, Yablonski ME, **Novack GD**, Cook DJ. True outflow facility determined by fluorophotometry in human subjects. *Exp. Eye Res* 1989;48:621-625.
  58. **Novack GD**, Leopold IH. Barriers to permeability: The blood-ocular and blood-brain barriers. *Am J Ophthalmol* 1988;105:412-16.
  59. Seamone C, LeBlanc R, Saheb N, **Novack GD**. Twice-daily levobunolol (0.5%) in the treatment of patients with deviated intraocular pressure. *Can J Ophthalmol* 1988;23:168-170.
  60. **Novack GD**, Kelley EP, Lue, JC. A multicenter evaluation of levobunolol (VISTAGAN®) in Germany. *Ophthalmologica* 1988;197:90-96.
  61. Weisweiler PS, Barnett PS, Chen KS, Kelley EP, **Novack GD**. Comparative comfort of flurbiprofen solution and indomethacin suspension eyedrops. *J. Clin Res Drug Develop* 1988;2:233-9.
  62. Rakofsky SI, Lazar M, Almog Y, LeBlanc RP, Lee P-F, Friedland BR, **Novack GD**, Kelley EP, Lue JC. Efficacy and safety of once-daily levobunolol for glaucoma therapy. *Can J Ophthalmol* 1989;24:2-6.
  63. Charap AD, Shin DH, Petursson G, Cinotti D, Wortham E, Brown RH, Silverstone DE, Atkins JM, Eto CY, Lue JC, **Novack GD**. The effect of varying drop size on the efficacy and safety of a topical beta blocker. *Ann Ophthalmol* 1989;21:351-7.
  64. **Novack GD**, Lue JC, Duzman E. Power estimates in designing glaucoma trials. *Glaucoma* 1989;11:166-168.
  65. Rakofsky SI, Melamed S, Cohen JS, Slight JR, Spaeth GL, Lewis RA, Zbrowski-Gutman L, Eto CY, Lue JC, **Novack GD**. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment. *Ophthalmology* 1989;96:8-11.
  66. **Novack GD**. Beta-blockers. *Ophthalmology Clinics of North America* 1989;2:77-96.
  67. Levobunolol Study Group. Levobunolol: A four-year study of efficacy and safety in glaucoma Treatment. *Ophthalmology* 1989;96:642-645.
  68. The Levobunolol Study Group. The effect of disease severity on the success rate of beta-blocker therapy in glaucoma. *Glaucoma* 1989;11:109-113.
  69. f Harper DG, **Novack GD**, Borrmann LR, Branin MJ. Dipivefrine, son mecanisme d'action, son efficacite clinique, sa bonne tolerance. [English version: Dipivefrin, mechanism of action, clinical efficacy and tolerance]. *Ophthalmologie* 1989;3:306-7.

70. Robin AL, **Novack GD**.  $\alpha_2$ -agonists in the therapy of glaucoma. IN: Applied Pharmacology of the Glaucomas, Drance SM, Van Buskirk EM, Neufeld AH (eds). Philadelphia. Williams and Wilkins, 1992, pp 103-124.
71. Introuini-Collison IB, Saghafi D, **Novack GD**, McGaugh JL. Adrenergic pharmacology of the memory-facilitating effect of dipivefrin, a lipophilic analog of epinephrine. Brain Res 1992;572:81-6.
72. Derick RJ, Robin AL, Tielsch J, Wexler JL, Kelley EP, Stoecker JF, **Novack GD**, Coleman A. Once-daily versus twice-daily levobunolol (0.5%) therapy: A crossover study. Ophthalmology 1992;99:424-429.
73. Blaydes JE, Kelley EP, Walt JG, DeGryse RE, Harper DG, **Novack GD**. Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification. J. Cataract Refract Surgery 1993;19:481- 487.
74. **Novack GD**. The development of new drugs for ophthalmology. Am J Ophthalmol 1992;114:357-364.
75. Miller IM, Vogel R, Cook TJ, Wittreich J, The Worldwide Norfloxacin Ophthalmic Study Group. Topically administered norfloxacin compared with topically administered gentamicin for the treatment of external ocular bacterial infections. Am J Ophthalmol 1992;113:638-644.
76. **Novack GD**, Robin AL, Derick RJ. New medical treatments for glaucoma. Int Ophthalmol Clin 1993;33:183-202
77. **Novack GD**. Ocular toxicology. Curr Opinion in Ophthalmology 1993;4 (VI):125-128.
78. **Novack GD**. Ocular toxicology. Curr Opinion in Ophthalmology 1994;5 (VI):110-114.
79. Wendel RT, Patel AC, Kelly NE, Salzano TC, Wells JW, **Novack GD**. Vitreous surgery for macular holes. Ophthalmology 1993;100 (11):1671-1676.
  
80. **Novack GD**. Development of New Drugs for Ophthalmology. In: Zimmerman TJ, Kooner K, Sharir M, Fetchner RD, eds. Textbook of Ocular Pharmacology. New York NY: Raven Press; 1997:151-163.
81. **Novack GD**. The ophthalmologist as clinical investigator. In: Zimmerman TJ, Kooner K, Sharir M, Fetchner RD, eds. Textbook of Ocular Pharmacology. New York NY: Raven Press; 1997:171-178.
82. Juzych MS, Robin AL, **Novack GD**. Alpha-2 agonists in glaucoma therapy. In: Zimmerman TJ, Kooner K, Sharir M, Fetchner RD, eds. Textbook of Ocular Pharmacology. New York NY: Raven Press; 1997:247-254.
83. Potter DE, **Novack GD**. Adrenergic pharmacology of the anterior segment. In: Zimmerman TJ, Kooner K, Sharir M, Fetchner RD, eds. Textbook of Ocular Pharmacology. New York NY: Raven Press; 1997:75-93.
84. Bartlett JD, **Novack GD**, Hiatt JA, Jaanus SD, Sharir M. Antiglaucoma drugs. IN: Clinical Ocular Pharmacology (3<sup>rd</sup> edition), Bartlett JD, Jaanus SD (eds), Boston, Butterworth-Heinemann, 1995, p. 183- 248.
85. **Novack GD**: Ocular toxicology. Curr Opinion in Ophthalmology 1995;6:108-112.
86. Cohen JS, Greff LJ, **Novack GD**, Wind BE. A placebo-controlled, double-masked evaluation of mitomycin-c in combined glaucoma and cataract procedures. Ophthalmology 1996;103:1934-1942.
87. Cohen JS, **Novack GD** , Li Li Z. The role of mitomycin treatment duration and previous intraocular surgery on the success of filtering procedures. J. Glaucoma 1997;6:3-9

88. **Novack GD.** Ocular toxicology. *Curr Opin in Ophthalmology* 1997;8:88-92.
89. Howes J, Novack.G.D. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite PJ-91 following chronic ocular administration. *J.Ocul.Pharmacol.Ther.* 1998;14:153-158.
90. **Novack GD.** Regulatory Review Intervals for Ophthalmic New Drug Applications at the U.S. Food and Drug Administration. *American Journal of Ophthalmology* 1998; 126:122-126.
91. **Novack GD.** Ophthalmic drug development: Procedural considerations. *J. Glaucoma* 1998;7:202-209.
92. Cloyd JC, Lalonde R, Beniak TE, and **Novack GD.** A single blind, crossover comparison of the pharmacokinetics and cognitive effects of a new rectal diazepam gel with intravenous diazepam. *Epilepsia* 1998;39:520-526.
93. Dell SJ, Lowry GM, Northcutt JA, Howes J, **Novack GD,** and Hart K. A Randomized, Double-Masked, Placebo-Controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. *J Allergy Clinical Immunology* 1998; 102:251-255.
94. Loteprednol Etabonate Post-operative Inflammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. *Ophthalmology* 1998; 105:1780-1786.
95. **Novack GD,** Howes J, Crockett RS, and Sherwood MB. Change in intraocular pressure during chronic use of loteprednol etabonate.. *J. Glaucoma* 1998; 7:266-269.
96. Robin, AL, **Novack, GD,** and Choplin, NT: "Medical Therapy for Glaucoma" in *Atlas of Glaucoma*, Choplin, NT and Lundy, DC, eds. Martin Dunitz, Ltd., London, UK, 1998, page 203-220.
97. Stewart RH, Horwitz B, Howes J, **Novack GD,** Hart K for the Loteprednol Etabonate Post-operative Inflammation Study Group 1. Double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. *J Cataract.Refract.Surg.* 24:1480-1489, 1998.
98. Shulman DG, Lothringer LL, Rubin JM, Briggs RB, Howes J, **Novack GD,** and Hart K. A Randomized, Double-Masked, Placebo-Controlled Parallel Study of Loteprednol Etabonate 0.2% in Patients with Seasonal Allergic Conjunctivitis. *Ophthalmology* 1999;106:362-369.
99. Shellenberger MK, Groves L, Shah J, **Novack GD.** A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state. *Drug Metabolism Distribution* 1999; 27:201-204.
100. Loteprednol Etabonate U.S. Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. *Am J Ophthalmology* 1999;127:537-544.
101. Toole WPJ, Lockhart L, Potrebka J, Bowman JP, **Novack GD.** Comparative irritancy study amongst Canadian retinoid creams and gels. *Journal of Cutaneous Medicine and Surgery* 1999;3:298-301.
102. **Novack GD.** ARVO Commercial relationships policy: Financial disclosure in ARVO presentations and publications. *Invest Ophthalmol Vis Sci* 1999;40:2765-2766.
103. Wax MB, **Novack GD,** Robin AL. Adrenergic agents. In: Albert DM, Jakobiec FA, Azar DT, Gragoudas ES, eds. *Principles and practice of ophthalmology*, 2<sup>nd</sup> ed. Philadelphia, PA: W.B.Saunders Company, 2000; chap. 26, pages 267-300.

104. **Novack GD**. Financing new drug development in ophthalmology. *J. Glaucoma* 2000;9:195-199.
105. Brown RH, **Novack GD**. General principles of ophthalmic medications. In: Morrison J, Pollack I, eds. *Glaucoma: Science and Practice*. New York, NY: Thieme Publishing Company, 2002; chap. 31., page 354-362.
106. **Novack GD**. Update on Regulatory Review Intervals for Ophthalmic New Drug Applications at the U.S. Food and Drug Administration. *Am J Ophthalmol*. 2000;130:664-665.
107. Mundasad MV, **Novack GD**, Allgood VE, Evans RM, Gorden JC, Yerxa BR. Ocular safety of INS365 ophthalmic solution: a P2Y<sub>2</sub> agonist, in healthy subjects. *J. Ocular Pharmacol Ther* 2001;17:173-179.
108. **Novack GD**. Drug development issues in pharmacological treatments for dry eye. *Lacrimal Gland, Tear Film and Dry Eye Syndromes 3: Advances in Experimental Medicine and Biology*, Eds: Sullivan DA, Stern ME, Tusbota K, Dartt DA, Sullivan RM, Bromberg BB. Kluwer Academic/Plenum Press, 2002,1117-1120.
109. **Novack GD**. Pharmacological Treatments for Dry Eye: A worthwhile investment! *Cornea* 2002;21:4-5.
110. **Novack GD**, Evans RM. Commercially available ocular hypotensive products: preservative concentration, stability, storage and in-life utilization. *J. Glaucoma* 2001;10:483-486.
111. **Novack GD**, O'Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population: Efficacy and safety. *Journal of the American Geriatric Society* 2002;50:956-62.
112. **Novack GD**. Pipeline: Keeping Tabs on New Ocular Pharmaceutical and Medical Device Products. *Ocul Surf* 2003;1 (1): 37.
113. Iwach AG, Delgado-Morales MF, Nguyen N, Wong PC, **Novack GD**, Dickens CJ. Transconjunctival Mitomycin-C in Needle Revisions of Failed Filtering Blebs. *Ophthalmology* 2003;110:734-742.
114. Delgado-Morales MF, Dickens CJ, Iwach AG, **Novack GD**, Nychka DS, Wong PC, Nguyen N. Long-term Results of Noncontact Transscleral Neodymium:YAG Laser Cyclophotocoagulation for Neovascular Glaucoma. *Ophthalmology* 2003;110: 895-899.
115. Kaufman B, **Novack GD**, Compliance issues in manufacturing of drugs. *Ocul Surf* 2003;1 (2): 80-85.
116. **Novack GD**. Emerging Drugs for Ophthalmic Diseases. *Expert Opinion on Emerging Drugs* 2003;8(1): 251-266.
117. **Novack GD**. Pipeline: How Are Tear Lubricant Products Regulated in the US? *Ocul Surf* 2003;1 (2):86.
118. **Novack GD**. Pipeline: Decoding the package insert: Indications. *Ocul Surf* 2003;1 (3):150-151.
119. **Novack GD**. Pipeline: Decoding the package insert: Adverse Events. *Ocul Surf* 2003;1 (4):202-3.
120. Siatkowski RM, Cotter S, Miller JM, Scher CA, Crockett RS, and **Novack GD** for the US Pirenzepine Study Group. Safety and Efficacy of 2% Pirenzepine Ophthalmic Gel in Children With Myopia: A 1-Year, Multicenter, Double-Masked, Placebo-Controlled Parallel Study. *Arch Ophthalmol* 2004;122:1667-74.
121. Driot JY, **Novack GD**, Rittenhouse KD, Milazzo C, Pearson PA. Ocular

- pharmacokinetics of fluocinolone acetonide after Retisert™ intravitreal implantation in rabbits over a one-year period. *J Ocular Pharm Ther* 2004;20 (3): 269-275.
122. Mundorf TK, Ogawa T, Naka H, **Novack GD**, and Crockett RS for the US ISTALOL Study Group. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of Timolol-LA once daily and timolol maleate solution twice daily in the treatment of adults with ocular hypertension or open-angle glaucoma. *Clin Ther* 2004;26(4):541-551
  123. **Novack GD**. Pipeline: The CONSORT statement for publication of controlled clinical trials. *Ocul Surf* 2004;2:45-6.
  124. **Novack GD**. Pipeline: Development of Topical Drugs. *Ocul Surf* 2004;2:166-168.
  125. **Novack GD**. Pipeline: Thoughts generated by the Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics. *Ocul Surf* 2004;2:212-214.
  
  126. Tan DTH, Lam DS, Chua WH, Shu-Ping,D.F.; Crockett,R.S.; **Asian Pirenzepine Study Group**. One-Year Multicenter, Double-Masked, Placebo-Controlled, Parallel Safety and Efficacy Study of 2% Pirenzepine Ophthalmic Gel in Children with Myopia. *Ophthalmology* 2005;112:84-91.
  127. **Novack GD**. Keeping current on medical information and drug development for dry eye disease. In: Asbell PA, Lemp MA, eds. *Dry eye disease: The clinician's guide to diagnosis and treatment*. New York, NY: Thieme Medical Publishers, Inc.; 2006:186-90.
  128. Mundorf TK, Ogawa T, Inui N, Naka H, **Novack GD**, and Crockett RS. Timolol LA: a double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers. *Curr Med Res Opin* 2005;21:369-373.
  129. **Novack GD**. Pipeline: What does it mean when a company says that a product is “approvable”. *Ocul Surf* 2005;3:63-4.
  130. **Novack GD**. Pipeline: Recent Patents in Dry Eye. *Ocul Surf* 2005;3:115-116
  131. **Novack GD**. Licensing compounds and handling of intellectual property: Mechanics of starting clinical trials. *Retina* 2005;25(8) Supplement: S96-S97.
  132. **Novack GD**. Pipeline: Should you be a clinical investigator for a new pharmaceutical?. *Ocul Surf* 2005;3 (3):168-170
  133. Reistad CE, Shields MB, Campbell DG, Ritch R, Wang JC, Wand M, and **American Glaucoma Society Pigmentary Glaucoma Iridotomy Study Group**. The Influence of Peripheral Iridotomy on the Intraocular Pressure Course in Patients With Pigmentary Glaucoma. *J.Glaucoma* 14 (4):255-259, 2005.
  134. Covert D, Robin AL, **Novack GD**. Systemic medications and glaucoma patients. *Ophthalmology* 2005;112 (10):1849-3.
  135. **Novack GD**. Is the world flat for pharmaceuticals? *Ocul Surf* 2005;3(4):212-4.
  136. **Novack GD**. Risks and benefits. *Ocul Surf* 2006;4(1):58-60.
  137. **Novack GD**. Research Ethics. *Ocul Surf* 2006;4(2):103-6.
  138. **Novack GD**. Bio-generics. *Ocul Surf* 2006;4:163-165.
  139. **Novack GD**. Treatment of retinal disorders: Challenges for the Small Company. 6<sup>th</sup> International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) 2006; 43-44.
  140. **Novack GD**. Adaptive trials. *Ocul Surf* 2006;4 (4): 59-61.

141. **Novack GD.** Pharmacotherapy: How much drug is there? *Ocul Surf* 2007;5 (1);58-61.
142. Hommer A, **Ganfort Investigators Group I.** A double masked, randomized, parallel, comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. *Eur J Ophthalmol* 2007;17:53-62.
143. Robin AL, **Novack GD,** Covert DW, Crockett RS, Marcic TS. Adherence In Glaucoma: Objective Measurements of Once-daily and Adjunctive Medication Use. *Am J Ophthalmol* 2007; 144:533–540.
144. **Novack GD.** The Role of Pharmaceutical Companies in Sponsored Research. *Ophthalmology* 2007;114;1037-1038.
145. Pflugfelder SC, Geerling G, Kinoshita S, Lemp MA.; McCulley J; Nelson D; **Novack GD;** Shimazaki J; Wilson C. Management and therapy of dry eye disease: Report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). *Ocul Surf* 2007;5:163-78.
146. **Novack GD.** Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. *Ann Rev Pharmacol Toxicol* 2008;48:61-78.
147. **Management and Therapy Subcommittee.** Management and Therapy of Dry Eye Disease: Report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop. *Ocul Surf* 2007;5:163-178.
148. **Novack GD.** Notification vs. Approval. *Ocul Surf* 2007;5:255-8.
149. Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I, for the **Ganfort® Investigators Group II Bimatoprost/Timolol fixed combination.** A 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. *J Glaucoma* 2008;17:211-216.
150. Siatkowski RM, Cotter S, Crockett RS, Miller JM, **Novack GD,** Zadnik K, for the U.S. Pirenzepine Study Group Two year multi-center, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% Pirenzepine Ophthalmic Gel in children with myopia. *J AAPOS* 2008;12:332-339.
151. **Novack GD.** Clinical trial registration. *Ocul Surf* 2007;5(4):316-317.
152. **Novack GD.** Orphan Drugs. *Ocul Surf* 2008;6 (1):52-55.
153. **Novack GD.** Conducting Clinical Trials: Even More Challenges. *Ocul Surf* 2008;6 (2):99-101.
154. **Novack GD.** What is a new drug? *Ocul Surf* 2008;6 (3): 143-146.
155. **Novack GD.** Clinical indications for ophthalmic corticosteroids. *Ocul Surf* 2008;6:199-202.
156. Stone JL, Robin AL, **Novack GD,** Covert D, Cagle GD. An Objective Evaluation of Eye-Drop Instillation in Glaucoma Patients. *Arch Ophthalmol* (in press).
157. **Novack GD.** Ophthalmic drug delivery: Development and Regulatory Considerations. *Clin Pharm Ther* 2009;85 (5): 539-543
158. **Novack GD.** The “in-between” New Drug Application. *Ocul Surf* 2009;7:53-55.
159. **Novack GD.** Just a small, proof of concept study. *Ocul Surf* 2009;7:111-114.f
160. Cohen JS, **Novack GD,** Zink JM. .Intraocular Pressure and Visual Field Damage as Risk Factors for Visual Field Progression in Filtering Surgery. *Ocular Surgery Lasers & Imaging* (in press).
161. **Novack GD,** Crockett R.S. Regression to the mean. *Ocul Surf* 2009;7: 163-165.

Publications of Gary D. Novack, Ph.D.

162. **Novack GD.** Clinical trial registration – Update. *Ocul Surf* 2009;7:212-214.
163. **Novack GD.** Data monitoring committees. *Ocul Surf* 2010;8:40-3.
164. **Novack GD.** Treatment adherence in ophthalmology and astrophysics. *Ocul Surf* 2010; 8 (2) 91-95.
165. **Novack GD.** Personalized Medicine and the Ocular Surface. *Ocul Surf* (in press).